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Chronic Q Fever Detection in
the Netherlands
Tot h eEditor—The article on the
current epidemic of Q fever in Holland,
which has involved more than 4000 di-
agnoses, is very interesting because it
makes it possible to make a preliminary
point on the detection of chronic in-
fection, the diagnosis of which is partic-
ularly difﬁcult [1]. One of the elements of
thediagnosisisserology,andthereisanold
consensus that the detection of immu-
noglobin G antibodies against phase I
antigens is the best method for the di-
agnosis of Q fever. Recently, using data
from our center, which has the most ex-
perience with the diagnosis of Q fever, we
revaluated the predictive value of anti-
bodies against phase I Coxiella burnetii [2].
Our results are comparable to those that
are presented here. Antibodies against
phase I antigens at a titer of 1/800 had
a positive predictive value of only 37%,
while antibodies at titers higher than 3200
had a positive predictive value of 75%.
Betweenthese2 titers, the diagnosis should
beconﬁrmedby polymerase chain reaction
(PCR) [3]. Itisnecessarytobecarefulwhen
analyzing serum samples with very high
antibody titers because, for an unknown
reason, the PCR is frequently negative in
these cases [3]. However, in the titer
window between 1/800 and 1/6400, PCR
plays a critical role in determining whether
the disease is progressing along with the
clinical conditions.
In all cases, it is necessary to be very
careful when estimating the incidence of
chronic Q fever because, as in a case re-
ported in this work, a diagnosis of chronic
Qfevercanbemadeupto10yearsafterthe
primary infection. In addition, we disagree
with the interpretation of the echographic
data cited here [4]. The valvulopathies
predisposing patients to Q fever endo-
carditis are, ﬁrst, prosthetic valves (which
are present in 0.5% to 1% of the popula-
tion in France) [5]; then, aortic bicuspidy
[6] (0.5%–2% of the population); more
rarely, mitral valve prolapse (0.6%–2.4%
of the population) [7, 8]; and even more
rarely, moderate aortic or mitral leaks (3%
of the population) [9]. It is not true that
more than50% of controls or patients with
acute Q fever have 1 or more of these
valvular lesions. The tiny traces of valve
insufﬁciency are physiological. However,
aortic bicuspid valve and mitral valve
prolapse can be clinically silent and must
be detected to avoid the evolution towards
chronicity. They account for 0.5%–3% of
the patients. Among patients with en-
docarditis following acute Q fever, com-
parisons of prevalence of the different
valvulopathies [10] with the correspon-
ding prevalence reported in a population
unexposedtoacuteQfeverinfection shows
the following gradient of risk: higher risk
for aortic bicuspidy 19.06 (95% CI [4.29–
84.63]), followed by 4.23 (2.08–8.58) for
the mitral valve prolapse and 20.06
(10.09–39.87) for a moderate mitral in-
sufﬁciency.Despitetheheterogeneityofthe
unexposed populations used to compute
these prevalence ratios, these results give
an important insight about priorities in
endocarditis prevention and clinical man-
agement of patients with valvulopathies.
In conclusion, given these data, it is
prematuretodecidethatechocardiography
is useless in detecting factors that pre-
dispose patients to endocarditis. Based on
our data, the failure to discover chronic
endocarditis in a patient diagnosed with
acute Q fever because that patient was not
evaluated for underlying predisposing fac-
tors by echocardiography at the time of
diagnosis may jeopardize the health of the
patient and put the physician at risk for
being sued.
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